|
|
RisperdalRather than allowing doctors to determine their patients' treatment--a core principle of the Medicare program--Congress created a drug benefit that allows insurance companies administering the drug benefit to limit treatment options. These limitations can have devastating consequences for people stabilized on mental health medications. Recognizing this potential, CMS has tried to impose minimum coverage standards but has failed to bar utilization management techniques that can effectively deny coverage to essential medicines. Utilization management techniques restrict access to medications included on a formulary in three ways. First, plans may require prior authorization before they will cover a certain drug, demanding that physicians certify specific diagnoses that are necessary for coverage. Second, they may impose step therapy--the requirement that an alternative, cheaper, medicine is first tried and shown to be ineffective or cause adverse side effects before a more expensive drug will be covered. Finally, plans can impose quantity limits on certain drugs. Quantity limits can specify the number of pills a particular drug a plan will cover each month or they can cap the total number of drugs it will cover at a set amount. A review of plan formularies finds that some plans require prior authorization or step therapy for the atypical antipsychotics Eisperdal and Zyprexa used to treat schizophrenia. Other plans impose quantity limits that limit the monthly dosage on these drugs and others in the same class. Among antidepressants, some plans place quantity limits, prior authorization or step therapy on Cymbalta, Zoloft and even generic Prozac. There are widespread reports of people with Medicare and those who advocate on their behalf finding it extremely difficult, if not impossible, to obtain prior authorization or an exemption to quantity limits from Part D plans. Among the most common problems is the inability to get through to the customer service lines to start the process to obtain coverage. The lack of standard prior authorization or formulary exceptions forms among plans also impedes the ability of plan enrollees, their physicians or counselors, to obtain approval for restricted drugs. These obstacles in turn have led to the refusal of some physicians to process the required paperwork and obtain the necessary documentation required by the plans. As a result, the utilization management restrictions imposed by plans act as a de facto exclusion of certain drugs, undermining the mandate that plans cover "substantially all" mental health drugs. It also subverts the goals of CMS guidance that deals specifically with the impact of utilization management techniques. For drugs that are covered, but subject to step-therapy or prior authorization restrictions, plans "should ensure that procedures limiting access are appropriate in situations in which a new enrollees is already stabilized on a drug or has already tried lower step agents."i For patients stabilized before enrollment on drugs in six classes-- antidepressants, antipsychotics, anticonvulsants, antineoplastics cancer medications ; , immunosuppressants and antiretrovirals, CMS expects that "plans would not use management techniques like prior authorization or step therapy, unless a plan can demonstrate extraordinary circumstances." ii The access problems reported during the first month of the drug benefit prompted CMS to tell plans they should also provide temporary supplies of drugs that are restricted by prior authorization or step therapy, as well as for drugs that are excluded from formularies. The. Subject: Aggressive Behavior Karen has a 6-year-old son who lately is doing a lot of hitting, scratching, pinching. He has sudden outbursts of anger and will also hit as a way of play. Her son takes Rispercal for sleeping and won't take his smaller dose in the morning. She was looking for advice. Here were some ideas that worked for one family: 1. Get a good handle on the ABCs of the behavior s ; - What happens just before the behavior antecedent ; , what is the behavior and what does it look sound feel and then what happens right AFTER your son displays the aggressive behavior the consequence ; . It's a good place to start to get some clues as to how often he's doing it, when, with whom, and how long it lasts etc. It may also give you some clues as to WHY he might be doing it and what communicative purpose the behavior is serving. What is he trying to communicate thru the behavior? 2. Let's say, you find that he's hitting the most when he seems to want to get the attention of or initiate play with a peer or sib. Now comes the fun part. What do you want him to do INSTEAD of the behavior hitting? Do you want him to go up peer and say something like, 'Do you want to play?' or communicate that in some other appropriate way? Then that's what you teach him to do INSTEAD of the hitting. 3. I used to do that 'quiet hands' thing a LOT with my daughter when she was little, not for hitting but for stimming. After about 6 months of me pulling my hair out and her continuing to stim with her hands, we did an 'ABC' and realized she mostly did it in situations where she was overwhelmed and this was her way of calming or entertaining herself with a visual stim. So instead of just telling her what NOT TO DO, we started teaching some acceptable alternatives that she COULD DO.and guess what? It worked. When medically appropriate, gradual discontinuation of the previous treatment is recommended while RISPERDAL therapy is initiated. In the case of depot injections, it is recommended that RISPERDAL not be administered until the next scheduled injection. Alterations in requirements of anti-Parkinson therapy may be required in patients switching to RISPERDAL. These requirements should be evaluated periodically. Adulthood ; . Risperdal's potential side effects, like others in its class, include weight gain that can lead to diabetes. Some physicians still swear by the older antipsychotics which carry some potentially very serious side effects especially when used for many years. Rjsperdal provides another option. Treatment options: Antipsychotic medication, such as thioridazine Mellaril ; , haloperidol Haldol ; , chlorpromazine Thorazine ; , clozapine Clozaril ; , or risperidone Rizperdal ; , may be prescribed. Cognitive therapy or psychotherapy may be employed to help the patient cope with the paranoia or persecutory delusions. If an underlying condition, such as depression or drug abuse, is triggering the paranoia, an appropriate course of medication or psychosocial therapy is employed to treat the primary disorder. 55. Alkadhi H, Kollias SS. MRI in tick-borne encephalitis. Neuroradiology 2000; 42: 753-5. Partlow GD, del Carpio-O'Donovan R, Melanson D, Peters TM. Bilateral thalamic glioma: review of eight cases with personality change and mental deterioration. AJNR J Neuroradiol 1992; 13: 1225-30. Guerini H, Helie O, Leveque C, Adem C, Hauret L, Cordoliani YS. Diagnosis of periventricular ependymal enhancement in MRI in adults. J Neuroradiol 2003; 30: 46-56. Shibata M, Kibe T, Fujimoto S, Ishikawa T, Murakami M, Ichiki T, et al. Diffuse central nervous system lupus involving white matter, basal ganglia, thalami and brainstem. Brain Dev 1999; 21: 337-40. Kashihara K, Nakashima S, Kohira I, Shohmori T, Fujiwara Y, Kuroda S. Hyperintense basal ganglia on T1weighted MR images in a patient with central nervous system lupus and chorea. AJNR J Neuroradiol 1998; 19: 284-6. Gizzi MS, Lidov M, Rosenbaum D. Neurosarcoidosis presenting as a tumour of the basal ganglia and brainstem: sequential MRI. Neurol Res 1993; 15: 93-6. Lee SH, Yoon PH, Park SJ, Kim DI. MRI findings in neuro-behcet's disease. Clin Radiol 2001; 56: 485-94 and zyban. Medications have been associated with side effects was false and misleading. In raising such broad-based concerns about antipsychotic medications, including longer-acting injectable formulations of conventional antipsychotics, defendants sought to conceal the special safety concerns that would accompany the use of Riwperdal when formulated using Medisorb technology for sustained release. To note these special safety concerns would have differentiated the - 16. Methods w-ere developed in the laboratory for the isolation and perfusion of the extremities, mid-gut, and liver in the experimental animal 9, 10 These procedures have also been applie l clinically for perfusion of the extremities, lung, breast, pelvis, oropharynx, and total body 2, 7, 8, To date seventy-three cases have been treate l by this method Among these there were seventeen patients with malignant melanomata, seventeen with sarcomata, and three with carcinomata involving the extremities. Perfusion of the lower extremity is accomplished through the external iliac, the common femoral, or the superficial femoral vessels, depending U0fl the location of the tumor. In the upper extremity, the subclavian, axillary, or brachial vessels are used. The technique for the isolation and perfusion of the lower extremity is as follows. With the patient under spinal or general anesthesia, the common femoral artery and vein are exposed through a and wellbutrin.
Table 2. Durations of the stages of labor. Mean duration Study group Control group Z n 100 ; n 100 ; test Mean SD Mean SD 2.45 0.55 P value.
By letter dated April 13, 2005, Board Staff advised Janssen-Ortho of the results of the price review of Risperdal Consta 25 mg, 37.5 mg, and 50 mg ; and that an investigation was commenced into the introductory price of Risperdal Consta. Attachment 10 ; In response, Janssen-Ortho filed additional materials on May 6, 2005 with Board Staff, reiterating its position that the prices of Risperdal Consta are not excessive. Attachment 11 ; Following its review of Janssen-Ortho's submission, Board Staff advised Janssen-Ortho by letter November 16, 2005 that it had completed its investigation and that the prices of Risperdal Consta continued to be excessive. Attachment 12 ; In fact, based on publicly available information in 2005, the prices of Risperdal Consta for all three DINs remain 2nd highest of the comparator countries listed in the Regulations and exceed the Median International Prices and prozac. CREATIVE DIRECTOR Currently driving patient & professional programs for the first healthcare-focused CRM agency Healthcare firsts? The #1 dermatologist-prescribed acne med, first-in-class migraine prevention, #1 hypertension drug, antibiotic success guarantee, blockbuster launch for asthma control. Clients include: AstraZeneca Crestor, Exanta, Symbicort, Toprol XL ; , Cephalon Provigil ; , Jansen Risperdal ; , Nestl Good Start infant formula ; , Novartis Elidel, Starlix ; , Ortho-McNeil Topamax, Levaquin ; , Ortho Neutrogena Retin-A Micro and desyrel. Depression, panic disorder and anxiety are a few examples of mood disorders -- complex medical conditions with varying degrees of severity. When using medications to treat mood disorders it is important to follow your doctors instructions. Remember to take your dose as directed even if you are feeling better, and do not stop unless you consult your doctor. In some cases it may take several weeks to see an improvement in symptoms. Risperdal online
A Reason to Hope fundraising event These statewide events will give you an insider's view of the impact the Alzheimer's Association makes in people's lives. See page 27 for dates and locations Memories Lost and Found AWARE's 7th annual signature luncheon is held on Thursday, November 9th. See page 26 for details. 17th Annual Education Symposium The Early Stage preconference is May 1st and the Symposium is on May 2nd and 3rd at the Holiday Inn DIA. Look for more information early next year and emsam.
By action of the Western Health Advantage Pharmacy and Therapeutics Committee, the following changes were made to the Commercial Preferred Drug List. Additions: Foradil formoterol ; , long acting beta-2 selective agonist for maintenance therapy of asthma. Formoterol is a dry powder for inhalation. Nasacort triamcinolone ; , added for patients on nasal inhaled steroids who do not like aqueous products replacement for Rhinocort, discontinued by manufacturer ; . New generics: * Tamoxifen generic Nolvadex ; added to all plans. Mirtazapine generic Remeron ; alternative generic antidepressant to fluoxetine. Nortrell 777 generic OrthoNovum 777 ; . Errin generic Micronor ; . Deletions: Remeron Soltab replaced with mirtazapine generic Remeron ; . Zyprexa olanzapine ; and Seroquel quetiapine ; made second line therapy for treatment failure or intolerable side effects to Risperdal or Geodon, per treatment protocol developed by Dr. Robert Hales and adapted by WHA P&T Committee. * Including Care Plus, Medicare Preferred Drug List.
Increased plasma concentrations of risperidone and 9-hydroxyrisperidone occur in patients with severe renal impairment creatinine clearance 30 ml min 1.73 m2 ; , and an increase in the free fraction of the risperidone is seen in patients with severe hepatic impairment. A lower starting dose should be used in such patients See DOSAGE AND ADMINISTRATION ; . Information for Patients Physicians are advised to discuss the following issues with patients for whom they prescribe RISPERDAL: Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration. Interference With Cognitive and Motor Performance: Since RISPERDAL has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that RISPERDAL therapy does not affect them adversely. Pregnancy: Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Nursing: Patients should be advised not to breast feed an infant if they are taking RISPERDAL. Concomitant Medication: Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-thecounter drugs, since there is a potential for interactions. Alcohol: Patients should be advised to avoid alcohol while taking RISPERDAL. Laboratory Tests No specific laboratory tests are recommended. Drug Interactions The interactions of RISPERDAL and other drugs have not been systematically evaluated. Given the primary CNS effects of risperidone, caution should be used when RISPERDAL is taken in combination with other centrally acting drugs and alcohol. Because of its potential for inducing hypotension, RISPERDAL may enhance the hypotensive effects of other therapeutic agents with this potential. RISPERDAL may antagonize the effects of levodopa and dopamine agonists. Chronic administration of carbamazepine with risperidone may increase the clearance of risperidone. Chronic administration of clozapine with risperidone may decrease the clearance of risperidone. Fluoxetine may increase the plasma concentration of the anti-psychotic fraction risperidone plus 9-hydroxyrisperidone ; by raising the concentration of risperidone, although not the active metabolite, 9-hydroxyrisperidone. Drugs that Inhibit Cytochrome P 450IID6 and Other P 450 Isozymes: Risperidone is metabolized to 9-hydroxyrisperidone by cytochrome P450IID6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs See CLINICAL PHARMACOLOGY ; . Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone. Analysis of clinical studies involving a modest number of poor metabolizers n 70 ; does not suggest that poor and extensive metabolizers have different rates of adverse effects. No comparison of effectiveness in the two groups has been made. In vitro studies showed that drugs metabolized by other P450 isozymes, including 1A1, 1A2, IIC9, MP, and IIIA4, are only weak inhibitors of risperidone metabolism. Drugs Metabolized by Cytochrome P 450IID6: In vitro studies indicate that risperidone is a relatively weak inhibitor of cytochrome P450IID6. Therefore, RISPERDAL is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. However, clinical data to confirm this expectation are not available. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis: Carcinogenicity studies were conducted in Swiss albino mice and Wistar rats. Risperidone was administered in the diet at doses of 0.63, 2.5, and 10 mg kg for 18 months to mice and for 25 months to rats. These doses are equivalent to 2.4, 9.4 and 37.5 times the maximum human dose 16 mg day ; on a mg kg basis or 0.2, 0.75 and 3 times the maximum human dose mice ; or 0.4, 1.5, and 6 times the maximum human dose rats ; on a mg m2 basis. A maximum tolerated dose was not achieved in male mice. There were statistically significant increases in pituitary gland adenomas, endocrine pancreas adenomas and mammary gland adenocarcinomas. The following table summarizes the multiples of the human dose on a mg m2 mg kg ; basis at which these tumors occurred. MULTIPLE OF MAXIMUM DOSE in mg m2 mg kg ; TUMOR TYPE SPECIES SEX LOWEST EFFECT LEVEL 0.75 9.4 ; 1.5 9.4 ; 0.2 2.4 ; 0.4 2.4 ; 6 37.5 ; 1.5 9.4 ; HIGHEST NO EFFECT LEVEL 0.2 2.4 ; 0.4 2.4 ; none none 1.5 9.4 ; 0.4 2.4 and geodon.
Were performed by using standard techniques as described by Kimura 17 ; , and the equipment used was Medelec MS 25 Mystro. Stimulating electrodes Medelec, bipolar stimulating electrode, 10 mm, code: 16894 ; , recording electrodes Medelec, bar recording electrode, 40 mm, code: 16934 ; , and ground electrodes Medelec, wraparound ground electrode, 2 mm, code: 54483 ; were used for all the stimulations and recordings. Lower and upper filter frequencies were 20 Hz to kHz for the motor nerve studies and 500 Hz to 10 kHz for the sensory nerve studies. Negative peak amplitude and peak-to-peak amplitude measurements were done for the motor and sensory responses, respectively. While studying extremities, skin temperature was kept between 32 and 34C. Measurement of F response latency was conducted with sweep duration of 100 ms frequency 5500 Hz, repetition rate 0.5 Hz ; . At least 10 consecutive stimuli were given and the minimum latency values observed were considered for evaluation. Statistical analysis All the results are given as means SD. Statistical analysis was made by GraphPad Instat, V2.02 software. Our data were tested and found suitable for evaluation with parametric tests. We used Student's t test for the comparisons among the groups, the paired t test for comparing the beginning and 6-month values, and the unpaired t test for the comparisons between placebo and vitamin E groups. In all the comparisons, two-sided P values were used. Descriptive statistics of the data and results of comparisons are given in Table 2. RESULTS -- Characteristics of the patients are shown in Table 1. Of the 21 patients enrolled in the study, 3 were men and 18 were women. The mean age of the study subjects was 58 years range 3575 years ; . Comparison of the groups revealed no statistical difference between age, BMI, and duration of disease P 0.05 ; . The respective changes of the HbA1 values during the 6-month treatment period within the placebo and the vitamin E groups were compared. The changes showed no statistical significance in each group P 0.05 ; . The groups were also compared with each other at the beginning and at the end of the study. No statistically significant difference was found between the groups for HbA1 levels both at the beginning and at the end of the study P. The Food and Drug Administration has determined that the treatment of behavioral disorders in elderly patients with dementia with atypical second generation ; antipsychotic medications is associated with increased mortality. Of a total of seventeen placebo controlled trials performed with olanzapine Zyprexa ; , aripiprazole Abilify ; , risperidone Risperdal ; , or quetiapine Seroquel ; in elderly demented patients with behavioral disorders, fifteen showed numerical increases in mortality in the drug-treated group compared to the placebo-treated patients. These studies enrolled a total of 5106 patients, and several analyses have demonstrated an approximately 1.6-1.7 fold increase in mortality in these studies. Examination of the specific causes of these deaths revealed that most were either due to heart related events e.g., heart failure, sudden death ; or infections mostly pneumonia. Getting off risperdal
I've read that a small dose of risperdal may help.
Risperdal pregnancy categoryRisperdak, rispe5dal, 4isperdal, 5isperdal, rizperdal, risperdaal, risperddal, tisperdal, r9sperdal, rusperdal, rispereal, risperdl, rispe4dal, risperdao, rispedral, risperda, r8sperdal, rispegdal, risperdwl, ripserdal, ris0erdal, rispedal, riseprdal, risperdql, risperdall, rsiperdal, risp3rdal, rislerdal, rispeddal, rispersal, rispwrdal, riserdal, risperal, risperxal, rispeerdal, rispercal, risperdsl, risp4rdal.Risperdal stroke lawyersRisperdal online, risperdal high, risperdal prescription medication, risperdal for bipolar depression and getting off risperdal. Risperdal pregnancy category, risperdal stroke lawyers, risperdal 0.2 mg and risperdal dose or risperdal alternative therapy. Risperdal 0.2 mgHeart failure journals, restoril narcotic, adenomyoma diagnosis, genotype websites and alcoholics anonymous 4th step worksheets. Remeron neurotransmitters, vocal cord warts, spider bites during sleep and quotes from the hangover or dilantin kinetics.
© 2009 |